Royalty Report: Drugs, Therapeutic, Disease – Collection: 213206

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 8

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Medical
  • Device
  • cardiac
  • Pharmaceuticals
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 213206

License Grant
The Irish Licensor grants the Licensee a worldwide license for the use of Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease.
License Property
Trelegy Ellipta is a prescription medication used to treat chronic obstructive pulmonary disease (COPD), a group of diseases that includes chronic bronchitis and emphysema.

COPD is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 286641

License Grant
Based on licensing and technology transfer agreement between the companies, upon initiation of sales of GLASSIA manufactured by Licensee which is expected to take place during 2021, Licensee will pay royalties to the Company.
License Property
The Companys flagship product is GLASSIA; the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration.

The Company is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.  AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties.

Field of Use
GLASSIA is proprietary product for the treatment of Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin (AAT) deficiency is a condition in which the body does not make enough of AAT, a protein that protects the lungs and liver from damage. The condition can lead to COPD and liver disease (cirrhosis).
Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term used to describe progressive lung diseases including emphysema, chronic bronchitis, and refractory (non-reversible) asthma. This disease is characterized by increasing breathlessness.

IPSCIO Record ID: 28235

License Grant
The Amendment expands the scope of the Licensee's license from the Licensor. Under the Cross-License Amendment, the Licensee will continue to develop the pulse program in the field of cardiopulmonary disease.
License Property
The Licensor manufactures and markets pharmaceutical drugs and devices.

INOpulse is based on the Company’s proprietary pulsatile nitric oxide delivery device. The Company is currently developing two product candidates under its INOpulse program: one for the treatment of pulmonary arterial hypertension, or PAH, for which the Company intends to commence Phase 3 clinical trials in the second half of 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH COPD, which is in Phase 2 development.

The INOpulse device is designed to be portable for use by ambulatory patients on a daily basis inside or outside their homes. The device is programmed to automatically adjust based on a patient’s breathing pattern to deliver a constant and appropriate dose of the inhaled nitric oxide over time, independent of the patient’s activity level, thus ensuring more consistent dosing in the alveoli of the lungs. In addition, we have developed a proprietary triple-lumen nasal cannula which enables more accurate delivery of the dose to the patient. The INOpulse device is also compatible with many long-term oxygen therapy systems that operate via a nasal cannula.

Field of Use
The Licensee will develop its Licensor pulse program for the treatment of three additional cardiopulmonary diseases: chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary hypertension associated with sarcoidosis and pulmonary hypertension associated with pulmonary edema from high altitude sickness.

IPSCIO Record ID: 6473

License Grant
The Company entered into its collaboration agreement to develop and commercialize a long-acting beta2 agonist (LABA) product candidate both as a single agent new medicine for the treatment of chronic obstructive pulmonary disease (COPD) and as part of a new combination medicine with an inhaled corticosteroid (ICS) for the treatment of asthma and/or a long-acting muscarinic antagonist (LAMA) for COPD.
License Property
The collaboration's resources are focused on the development of the lead LABA, GW642444, together with fluticasone furoate.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 49323

License Grant
The parties wish to amend certain provisions of the Supply Agreement to, among other things, change the pricing terms; and the parties wish to amend certain provisions of the License Agreement to, among other things, add royalty terms, as additional consideration for the Products to be supplied under the Supply Agreement.
License Property
INOpulse is based on the Company’s proprietary pulsatile nitric oxide delivery device and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH COPD.  The INOpulse device is designed to be portable for use by ambulatory patients on a daily basis inside or outside their homes. The device is programmed to automatically adjust based on a patient’s breathing pattern to deliver a constant and appropriate dose of the inhaled nitric oxide over time, independent of the patient’s activity level, thus ensuring more consistent dosing in the alveoli of the lungs.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 6157

License Grant
The Licensee entered into a licensing agreement with a former shareholder for the commercialization of either of the VPAC2 analogs for any purpose.
License Property
Diabetes – VPAC2 agonists exert their effects through a separate receptor pathway than incretinin mimetic drugs like GLP-1 agonists ((i)Byetta®), and DPP-IV inhibitors ((ii)Januvia®). By targeting selective VPAC2 receptors, the FM-TP2000 series of analogs are designed to mimic the natural, neuronal signal, rather than the hormonal one, to stimulate beta cells to release insulin in a glucose-dependent fashion. This provides an alternative therapeutic approach, which could achieve benefits similar to Byetta, but may also be complementary in effect.

Inflammatory Lung Disease  – VPAC2 agonists have bronchodilating, and anti-inflammatory effects. By targeting VPAC2 receptors, the FM-TP3000 series of compounds are designed to suppress the release of inflammatory mediators (TNF-alpha, IL-12), as well as suppressing the eosinophil response to stimuli. This provides an alternate therapeutic approach to treating asthma, chronic obstructive pulmonary disease (COPD), and Pulmonary Arterial Hypertension (PAH).

Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 203566

License Grant
The parties entered into to a Research and Development Agreement dated March 10, 1997 relating to EPI-HNE4, an inhibitor of human neutrophil elastase.  The Parties now enter into this Agreement for thecommercialization of the results of the Research and Development Agreement.

Licensor grants the Swiss Licensee an exclusive license with the right to sublicense during the term of this Agreement, under the EPI-HNE Patent Rights, EPIHNE Technology, the cystic fibrosis or CF Know-How and CF Patent Rights, to develop, use, offer for sale, sell, have sold, import and export CF Product in the Territory and to make or have made or to purchase or have purchased CF Product for such purposes.

Licensor grants exclusive license with the right to sublicense during the term of this Agreement, under the EPIHNE Patent Rights, EPI-HNE Technology, the applicable CF Know-How and CF Patent Rights, to develop, use, offer for sale, sell, have sold, import and export any Other Product in the Territory and to make or have made or to purchase or have purchased such Other Products for such purposes.

License Property
The EPI-HNE Technology shall mean molecules, including EPI-HNE4, recombinant strains that produce EPI-HNE4 and methods of purifying EPI-HNE4 from recombinant organisms, and other protein molecules with anti-neutrophil elastase activity as described in the EPI-HNE Patent Rights.

The Product is for cystic fibrosis.

Field of Use
The field means human therapeutic uses solely for the treatment of cystic fibrosis, acute respiratory distress syndrome ('ARDS'), and chronic obstructive pulmonary diseases (COPD), such as emphysema and chronic bronchitis.

IPSCIO Record ID: 204327

License Grant
Swiss Licensor grants to Licensee, under the cystic fibrosis or CF Know-How and the CF Patent Rights:
– an exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export CF Product in North America and to make or have made or to purchase or have purchased CF Product for such purposes;
– an exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export CF Product outside of the Territory and outside of North America and to make or have made or to purchase or have purchased CF Product for such purposes;
– an exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export Other Products outside of the Territory and to make or have made or to purchase or have purchased Other Products for such purposes;
– a worldwide exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export therapeutic products outside of the Field of Use and to make or have made or to purchase or have purchased therapeutic products outside the Field of Use for such purposes;
– a worldwide exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export non-therapeutic products and to make or have made or to purchase or have purchased non-therapeutic products for such purposes.
License Property
The EPI-HNE Technology shall mean molecules, including EPI-HNE4, recombinant strains that produce EPI-HNE4 and methods of purifying EPI-HNE4 from recombinant organisms, and other protein molecules with anti-neutrophil elastase activity as described in the EPI-HNE Patent Rights.

The Product is for cystic fibrosis.

Field of Use
The field means human therapeutic uses solely for the treatment of cystic fibrosis, acute respiratory distress syndrome ('ARDS'), and chronic obstructive pulmonary diseases (COPD), such as emphysema and chronic bronchitis.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.